Aquaculture Europe 2025

September 22 - 25, 2025

Valencia, Spain

Add To Calendar 24/09/2025 11:45:0024/09/2025 12:00:00Europe/ViennaAquaculture Europe 2025DEVELOPMENT OF AN EFFICACIOUS AND SAFE VACCINE AGAINST VIRAL NERVOUS NECROSIS (VNN) IN EUROPEAN SEA BASS Dicentrarchus labraxAUD 3, VCC - Floor 0The European Aquaculture Societywebmaster@aquaeas.orgfalseDD/MM/YYYYaaVZHLXMfzTRLzDrHmAi181982

DEVELOPMENT OF AN EFFICACIOUS AND SAFE VACCINE AGAINST VIRAL NERVOUS NECROSIS (VNN) IN EUROPEAN SEA BASS Dicentrarchus labrax

Tove Hansen*, Trygve Eliassen, Inge Tom Solbakk,  Stian Brekke and Terje Tingbø

 

Pharmaq part of Zoetis, Harbitzalléen 2A, 0275 Oslo, Norway

 E-mail: tove.hansen@zoetis.com

 



Introduction

 Viral Nervous Necrosis (VNN), also known as Viral E ncephalopathy and Retinopathy (VER), is caused by a virus belonging to the genus Betanodavirus of the Nodaviridae family. The disease has been described in more than 50 fish species and is still considered a serious threat to aquaculture .  Farmed European sea bass is severely affected , the virus is causing animal suffering and significant losses to the industry. Because of the need for preventive measures, Pharmaq developed a vaccine  against  VNN and the demand for vaccines is growing.

Methods and Results

Development of the monovalent injection vaccine targeting Viral N ervous N ecrosis V irus (VNNV) was initiated in 2012 and extensive research and documentation continued up to 2017 when the first Marketing Authorization was granted.  Developing a robust and reproducible challenge model is key to be able to test and document vaccine efficacy. Protection was assessed clinically* through dose-response studies, evaluation of onset- and duration of immunity, and cross protection testing using  challenge isolates of various origin. The safety of the vaccine, including local reactions such as abdominal adhesions and pigmentation, was investigated after vaccination .  Extensive clinical testing under controlled  laboratory  conditions showed that the vaccine is safe to use and provides high levels of protection, which has been  further supported by experience from the field.  Data have also been gathered after large scale commercial use of the vaccine, and feedback from farmers has been vital to monitor efficacy and safety.

 This presentation will review the highlights of the development process, with a special focus on clinical studies. Current field situation  will also be addressed.

*The pre-clinical studies were conducted in line with the “License to Carry out Research on Animals” granted to AquaBioTech Group by the Ministry for Agriculture, Fisheries, Food and animal rights, Animal welfare Department in Malta and in accordance with procedures approved by the Zoetis Animal Ethics Committee.